Complicated Skin and Skin Structure Infections
📧 Sign up to get email alerts when something new happens for Complicated Skin and Skin Structure Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2011-09-28Clinical Trial Update: Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use
A study evaluating the safety and efficacy of Cubicin (daptomycin) under real-use conditions has been withdrawn.
-
CLINICAL_TRIALS safety_alert · 2011-07-08Clinical Trial Update: Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
Post-marketing safety study of tigecycline (Tygacil) completed; results posted, evaluating safety in patients with complicated skin and skin…
-
FDA approval · 2011-06-29FDA Approved: TEFLARO — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for TEFLARO (ceftaroline fosamil) submitted by Allergan, Inc., under NDA 200327.
-
CLINICAL_TRIALS trial_result · 2011-01-05Clinical Trial Update: Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections [Phase 3]
Phase 3 trial comparing daptomycin to vancomycin or teicoplanin for complicated skin and skin-structure infections; the study was terminated…
-
CLINICAL_TRIALS trial_result · 2010-12-23Clinical Trial Update: Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections [Phase 4]
A Phase 4 trial assessed the safety and efficacy of daptomycin for complicated skin and skin-structure infections. The study was terminated …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-09-14Clinical Trial Update: Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections [Phase 2]
A completed Phase 2 trial evaluating the safety and efficacy of daptomycin for complicated skin and skin-structure infections (soft tissue i…
-
CLINICAL_TRIALS trial_result · 2009-12-08Clinical Trial Update: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus [Phase 3]
Phase 3 trial comparing telavancin with vancomycin for complicated skin and skin structure infections, including MRSA, with results posted.
-
FDA approval · 2009-09-11FDA Approved: VIBATIV — Original Application (Cumberland Pharmaceuticals Inc.)
FDA approved Vibativ (telavancin hydrochloride) through an original NDA for the treatment of hospital-acquired bacterial pneumonia and compl…
-
CLINICAL_TRIALS trial_result · 2009-06-03Clinical Trial Update: Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection [Phase 2]
Phase 2 study evaluating safety, potential efficacy, and pharmacokinetics of PZ-601 for complicated skin and skin structure infections; the …
-
CLINICAL_TRIALS trial_result · 2007-12-28Clinical Trial Update: Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI [Phase 4]
A Phase 4 trial evaluating the safety and efficacy of tigecycline for complicated skin and skin-structure infections in hospitalized patient…
-
FDA approval · 2007-04-26FDA Approved: LINEZOLID — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for LINEZOLID submitted by Mylan Pharmaceuticals Inc., associated with updates to the product’s …
-
FDA approval · 2007-04-03FDA Approved: TYGACIL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for TYGACIL (tigecycline) by Wyeth Pharmaceuticals (a Pfizer subsidiary), indicating regulatory …
-
CLINICAL_TRIALS trial_result · 2007-03-27Clinical Trial Update: Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2) [Phase 3]
A Phase 3 trial (ASSIST-2) comparing intravenous iclaprim to linezolid for complicated skin and skin structure infections has completed.